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use#LAAWe conducted a retrospective study of the clinical
aspects of bacteremia caused by methicillin-resistant
Staphylococcus aureus (MRSA) with heterogeneously
reduced susceptibility to vancomycin. Bloodstream MRSA
isolates were screened for reduced susceptibility by using
brain-heart infusion agar, including 4 mg/L vancomycin with
and without 4% NaCl. Patients whose isolates exhibited
growth (case-patients) were compared with those whose
isolates did not (controls) for demographics, coexisting
chronic conditions, hospital events, antibiotic exposures,
and outcomes. Sixty-one (41%) of 149 isolates exhibited
growth. Subclones from 46 (75%) of these had a higher
MIC of vancomycin than did their parent isolates. No iso-
lates met criteria for vancomycin heteroresistance. No dif-
ferences in potential predictors or in outcomes were found
between case-patients and controls. These data show that
patients with vancomycin-susceptible MRSA bacteremia
have similar baseline clinical features and outcomes
whether or not their bacterial isolates exhibit growth on
screening media containing vancomycin.
S
taphylococcus aureus is an important cause of illness
and death and accounts for about one-fifth of bac-
teremia cases in the United States (1). In 1997, Hiramatsu
et al. reported the first clinical strain of methicillin-resist-
ant S. aureus (MRSA) that exhibited reduced susceptibili-
ty to vancomycin (2). Areport of other such isolates, clas-
sified as vancomycin-intermediate S. aureus (VISA), soon
followed (1). Infection with VISA has been associated
with vancomycin treatment failures, but it is a rare phe-
nomenon, with worldwide prevalence limited to isolated
case reports and a single limited outbreak (1,3). Rarer still
in S. aureus is the phenomenon of vancomycin resistance
(VRSA), with only two clinical VRSA isolates reported to
date, both in 2002 (4,5). 
Far more common than VRSA and VISA, however, are
MRSA isolates that exhibit “heteroresistance” to van-
comycin (hetero-VISA), whereby subpopulations within
the strain exhibit reduced susceptibility, although the over-
all MIC for the isolate is within the susceptible range (<4
mg/L). Arecent survey in Japan found this phenotype in up
to 26% of clinical MRSA isolates collected in university
hospitals (6).
Clinical laboratories do not perform heteroresistance
testing for a number of reasons: Such testing is cumber-
some, no standardized testing methods exist, and, perhaps
most important, the clinical significance of this phenotype
is not known (7). Although clinical MRSAisolates exhibit-
ing hetero-VISA have now been reported from several
countries (7–16), no study has demonstrated that patients
with infections caused by these strains fare differently than
patients with comparable infections caused by MRSA
strains that are homogeneously susceptible to vancomycin.
Throughout this article, we use the following terms to
describe different phenotypic features of S. aureus isolates:
Vancomycin-susceptible S. aureus (VSSA) refers to iso-
lates that are susceptible to vancomycin, according to
NCCLS criteria (MIC <4 mg/L) (1). VISA refers to iso-
lates that have intermediate susceptibility to vancomycin
per NCCLS criteria (MIC 8–16 mg/L) (17). Hetero-VISA
refers to isolates for which the MIC of vancomycin for one
or more subpopulations is >4 mg/L, whereas the overall
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Many investigators who have looked at hetero-VISA
(so named because the resistant subclones have intermedi-
ate susceptibility) have first screened for reduced suscepti-
bility to vancomycin and then confirmed hetero-VISA sta-
tus by demonstrating MICs above the susceptible range
(i.e., >4 mg/L) among subclones of those isolates with pos-
itive screening results (6,9,10,12–16). No study has exam-
ined isolates that meet screening criteria yet fail to qualify
as hetero-VISA on confirmatory testing. Such isolates are
composed of subpopulations that, although susceptible to
vancomycin, demonstrate varying degrees of susceptibili-
ty. Thus they may be capable of a certain degree of growth
on screening media containing vancomycin, despite an
absence of subpopulations that demonstrate intermediate
resistance to vancomycin by MIC criteria. If, as has been
suggested, VISA arise from homogeneously vancomycin-
susceptible S. aureus through a multistep process (18), het-
ero-VISA and, ultimately, VISA may be selected from just
such a population of isolates that display heterogeneously
reduced susceptibility to vancomycin but do not meet cri-
teria for hetero-VISA. We studied patients with MRSA
bacteremia in our institutions to determine the prevalence,
among the infecting strains, of hetero-VISA, and of non-
hetero-VISA isolates that nevertheless exhibited varying
degrees of susceptibility to vancomycin among subpopula-
tions. Additional objectives were to identify factors predic-
tive of bacteremia with such isolates and to determine
whether bacteremia with such isolates affected patient out-
comes.
Methods
Microbiologic Methods
Bacterial Isolates 
MRSA bloodstream isolates that had been stored nons-
electively at Beth Israel Deaconess Medical Center from
September 1998 through November 2001 and nosocomial
bloodstream isolates from patients in intensive care units at
Johns Hopkins Hospital from July 1997 through April 2000
were used. In addition, the following strains were used as
controls: ATCC 29213 (Methicillin-susceptible S. aureus),
ATCC 33591 (vancomycin-susceptible MRSA), ATCC
51299 (vancomycin-resistant Enterococcus faecium) and
PC3 (VISA strain contributed by A. Tomasz) (19).
Screening for Heterogeneously Reduced
Susceptibility to Vancomycin 
Suspensions of 0.5 McFarland turbidity standard in
brain heart infusion (BHI) broth were prepared from iso-
lates after overnight incubation. Ten microliters of each
suspension was injected onto BHI agar plates containing 4
mg/L vancomycin. Because of the reported inducibility of
vancomycin heteroresistance in some strains of S. aureus
by NaCl (13), each isolate was screened on agar with and
without 4% NaCl supplementation. 
Plates were incubated at 35°C. Results were recorded
after 24 h and 48 h of incubation. For any growth in excess
of a single pinpoint colony on screening media, either with
or without 4% NaCl supplementation, a positive result was
recorded.
Susceptibility Testing
Susceptibility to vancomycin was determined by agar
dilution, according to NCCLS guidelines (17), with
Mueller-Hinton agar. Testing was performed on all MRSA
bloodstream isolates (parent isolates), as well as on those
colonies that grew on screening media (subclones). MIC
testing was performed on colonies taken from the screen-
ing agar on which they exhibited optimal growth (i.e., BHI
agar containing 4 mg/L vancomycin, with or without 4%
NaCl).
Identity Confirmation and Strain Typing 
The identity of parent isolates and subclones was con-
firmed by Gram stain, catalase testing (20), and latex
agglutination testing (Staphaurex, Murex Biotech, Ltd.,
Dartford, UK). Strains were grouped by type and subtype
by using pulsed-field gel electrophoresis (PFGE) (21).
Plugs were made by using standard techniques.
Macrorestriction was performed with SmaI (22).
Population Analysis 
Suspensions of 3.0 McFarland turbidity standard in
BHI broth were made from overnight cultures of selected
parent isolates and subclones. Subclones were grown in 4
mg/L vancomycin before suspension in broth. Seven seri-
al 10-fold dilutions of each suspension were prepared.
Twenty-five microliters of each suspension and dilution
was injected twice onto BHI agar containing 4% NaCl, at
vancomycin concentrations of 0 mg/L, 1 mg/L, 2 mg/L, 4
mg/L, and 8 mg/L. NaCl was added due to the enhanced
growth we observed on NaCl-containing media during
screening. Colonies were counted after 48 h of incubation
at 35°C, and sums of each inoculum pair were averaged.
Epidemiologic Methods
Clinical Data Collection and Inclusion Criteria
For the epidemiologic analysis, the unit of observation
shifted from the bacterial isolate to the patient with bac-
teremia. Demographic and clinical data for the patients
with saved MRSA bloodstream isolates were collected
from electronic medical records and from hospital databas-
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regardless of the number of isolates generated during the
study period. Patients with multiple isolates were included
at the time MRSA was first isolated from the bloodstream
and the isolate grew on screening media. Those patients
whose isolates never grew on screening media were
included at the time of their first MRSA bloodstream iso-
lation. Inpatients only were considered in the analysis. The
study was approved by the ethics review boards of Beth
Israel Deaconess Medical Center and of Johns Hopkins
Hospital and performed at both institutions.
Study Design
We conducted a two-part retrospective analysis on
patients with MRSA bacteremia: a case-control analysis,
which considered the clinical features at the time of cul-
ture, and a cohort analysis, which evaluated outcomes after
culturing. 
For the case-control study, patients whose MRSA
bloodstream isolates exhibited growth on screening media
(case-patients) were compared with patients whose iso-
lates exhibited no growth (controls), in terms of the fol-
lowing features: age, sex, coexisting chronic conditions,
hospital events, and antibiotic exposures before culture.
Particular attention was given to exposure to vancomycin,
examined both as a dichotomous variable and for cumula-
tive days of exposure.
In the cohort study, we compared the above two groups
of participants for the following postculture outcomes:
deaths, discharge disposition, and duration of hospital stay
after culture. Possible confounding variables were evaluat-
ed through multivariate modeling.
Statistical Analysis
Statistical analyses were performed by using SAS sta-
tistical software (version 8e, SAS Institute, Inc., Cary,
NC). Continuous variables were compared by using the
Student t test or the Wilcoxon rank sum test, depending on
the normality of the distribution. Binary variables were
compared by using the Fisher exact test. Nonbinary cate-
gorical variables were compared by using the chi-square
test. Multivariate logistic regression models were used in
the death and disposition analyses to control for confound-
ing. A Cox proportional hazards model was used in the
time-to-discharge analysis; observations were censored at
patient’s death. For all statistical tests, a p value of <0.05
was considered significant. 
Results
Microbiologic Results
We tested 173 MRSA bloodstream isolates from 154
patients. For the following reasons, we excluded 24 iso-
lates from the analysis: 19 represented additional isolates
from patients already included in the cohort, 4 came from
outpatients, and 1 came from a patient whose hospital stay
extended beyond the study period. Thus, we evaluated 149
isolates, each cultured from the blood of a unique inpa-
tient, and will describe them here.
All isolates were susceptible to vancomycin (MIC50, 1
mg/L; MIC90, 1 mg/L; range 0.5–2 mg/L). Isolates from 61
patients (41% of the patient cohort) grew on screening
media within 48 h. Subclones of 46 of these isolates (75%)
exhibited a two- to fourfold increase in MIC compared
with the parent strain. No subclones, however, exceeded
the 4 mg/L NCCLS breakpoint for vancomycin suscepti-
bility (the MIC of vancomycin for all but one subclone was
<2 mg/L; for one subclone it was 4 mg/L) (1). We there-
fore did not characterize any of the isolates as hetero-
VISA. We characterized isolates with positive results on
our screening assay as having heterogeneously reduced
susceptibility to vancomycin.
The isolates comprised 11 different PFGE types. We
assigned letters and numbers to PFGE types and subtypes,
respectively. One hundred and three (69%) were variants
of type A, which had 35 different subtypes. Twenty-two
(15%) were variants of type B, which had seven different
subtypes. The remaining 24 isolates (16%) consisted of
nine different types. Type A was associated with the
absence of heterogeneously reduced susceptibility (odds
ratio [OR] 0.35; p=0.004), whereas type B was associated
with its presence (OR 4.86; p=0.002). The results of strain
typing and the relationship between type and screening
results are summarized in Table 1. Figure 1 shows the
results of PFGE performed on several isolates.
We performed population analysis on eight isolates
(four that exhibited growth on screening media and four
with no growth) to determine the utility of population
analysis in distinguishing between these two types of iso-
lates. The results, represented graphically in Figure 2a, do
not enable such a distinction to be made. A shift in the
curve is apparent, however, for two isolates with positive
screening results from the same patient cultured 14 months
apart. For the earlier isolate, the MIC of vancomycin was
0.5 mg/L. For the later isolate, cultured after several inter-
val admissions for MRSA bacteremia in which the patient
received vancomycin, the MIC was 1.0 mg/L, and an
upwardly shifted population curve (signifying a greater
proportion of the population with higher MICs of van-
comycin) was observed. Asubsequent population analysis,
run on selected parent-subclone pairs for isolates that grew
on screening media, demonstrated an upward shift in the
population curve for the subclone versus the parent when
a corresponding increase in MIC existed. A representative
population curve is shown in Figure 2b.  
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A comparison of patients with isolates with positive
screening results (cases) to those with negative results (con-
trols) demonstrated no significant differences in terms of
age, sex distribution, coexisting chronic conditions, recent
hospitalization, or hospital events before culture (Table 2).
Similarly, no differences were found between the groups
with respect to administration of any antibiotic, administra-
tion of vancomycin specifically, or number of days of van-
comycin exposure before culture (Table 3). In the cohort
analysis of the impact of the screening phenotype on patient
outcomes, no differences were noted between case-patients
and controls in the proportion who died during hospitaliza-
tion (p=1.00; adjusted for severity of illness, p=0.98) or dis-
charge disposition (Table 4). Similarly, for patients who
survived until discharge, the time to discharge did not dif-
fer between the two groups (hazard ratio 0.99; 95% confi-
dence interval, 0.67 to 1.47; p=0.97) after controlling for
duration of stay prior to culture.
Given the absence of standardized criteria for determin-
ing the screening phenotype, we further analyzed the data
using a number of more stringent definitions. If we consid-
ered growth on screening media within 48 h with an asso-
ciated increase in MIC among the subclones as the criteria
for a positive screening result (n=46), again no significant
predictors of the phenotype and no differences in outcomes
were found. Twenty patients (13%) had isolates that grew
on screening media within 24 h. Using this characteristic
as the screening criterion, we found that the only signifi-
cant predictor of this phenotype was intensive care unit
stay before culture (OR 2.95; 95% confidence interval 1.07
to 8.15; p=0.05); no differences in outcomes were found
(data not shown).
Finally, since the criteria for isolate collection were not
identical in the two study institutions, we performed a sub-
group analysis using data from Beth Israel Deaconess
Medical Center patients alone (n=120). This analysis did
not change the results using the 48-h growth cutoff.
Analysis of these data using the 24-h cutoff showed dia-
betes mellitus to be the only significant predictor of hetero-
geneously reduced susceptibility to vancomycin (OR 3.52;
95% confidence interval, 1.04 to 11.96; p=0.05), with no
differences in outcomes (data not shown).
Discussion
First reported in a clinical specimen from Japan in 1997
(2), VISA strains (MIC 8–16 mg/L) (17) have now been
isolated in numerous countries around the world (3,24,25)
and have been identified in several patients in the United
States (7,19,26). These patients have in common extensive
prior exposure to vancomycin, and their clinical courses
are notable for a suboptimal response to this agent (1,7).
Since VISA isolates are presumed to spread as do van-
comycin-susceptible strains of S. aureus, their appearance
has prompted the issuance of guidelines for their identifi-
cation and control of transmission (27,28).
Shortly after the report of the first VISA isolate was
published, Hiramatsu et al. reported an S. aureus isolate
exhibiting heteroresistance to vancomycin (6). They found
this phenotype of vancomycin heteroresistance to be wide-
spread in Japanese university hospitals. In the ensuing 5
years, reports emerged of heteroresistant S. aureus in
numerous countries (6–16).
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Table 1. Strain typing and relationship to reduced vancomycin susceptibility screening results  
  No. isolates  Positive results on screening   Odds ratio (95% confidence interval)   p 
Type A  103  34 (33%)  0.35 (0.17 to 0.71)   0.004 
Type B  22  16 (73%)  4.86 (1.87 to 13.29)  0.002 
Other type  24  11 (46%)  -  - 
Figure 1. Pulsed-field gel electrophoresis of selected isolates,
demonstrating predominant and secondary types. Lane 1,
Staphylococcus aureus NCTC 8325, used as DNA molecular
weight reference marker; lanes 2 and 3, clinical isolates of type
A13; lane 4, clinical isolate of type A1; lane 5, clinical isolate of
type B2; lane 6, clinical isolate of type H.Several areas of uncertainty have marked the subject of
vancomycin heteroresistance since it was first described.
First, no standardized definition exists, and investigators
have defined it by using a variety of criteria
(6,8,11,16,29,30). Second, the clinical significance of het-
eroresistance remains unclear. Although existing evidence
supports the hypothesis that heteroresistant isolates have a
greater likelihood of developing homogeneous intermedi-
ate resistance than do susceptible strains (6), and other data
suggest an association between isolation of VISA and an
adverse outcome (7), few studies have examined whether
specific risk factors exist for infection with hetero-VISA,
and whether such infection is associated with adverse out-
comes. Those studies that have examined risk factors have
had small sample sizes (10), inadequate generalizability
(8), or a method of control selection that did not allow for
direct comparison between patients with hetero-VISA and
those infected with S. aureus isolates that were homoge-
neously susceptible to vancomycin (13). No study before
ours has explored the clinical implications of varying
degrees of vancomycin susceptibility in MRSA isolates
that do not qualify as hetero-VISA.
This study addresses the prevalence of vancomycin het-
eroresistance among bloodstream MRSA isolates at two
large, urban teaching hospitals and explores clinical corre-
lates of bacteremia with isolates exhibiting heterogeneous-
ly reduced vancomycin susceptibility, as defined by
growth on vancomycin screening agar (vancomycin 4
mg/L). We chose a screening method to encompass as
broad an array of potentially heteroresistant isolates as
possible. By subjecting subclones to agar dilution, howev-
er, we were deliberately conservative, in order to deter-
mine whether our isolates fulfilled Hiramatsu’s criteria for
vancomycin heteroresistance in as unambiguous a manner
as possible (6). Although none of our isolates were charac-
terized as hetero-VISAunder these strict criteria, over 40%
had subpopulations capable of growth on our vancomycin-
containing screening media. Such findings are plausible
because  S. aureus strains are known to differ in their
propensity to develop reduced susceptibility to van-
comycin (31). It is possible that some or all of the isolates
from our cases are potential precursors of truly heteroresis-
tant isolates (hetero-VISA), which may in turn be forerun-
ners of VISA (7,18,32).
Howe et al. have criticized the method of screening for
vancomycin heteroresistance in the presence of the antibi-
otic, followed by MIC testing of subclones, as being poor-
ly reproducible and potentially selecting for, rather than
simply detecting, resistant mutants (29). Regarding repro-
ducibility, we repeated screening for 12 clinical isolates (6
with initially positive results, and 6 with negative results)
at different times, using freshly made media each time. Ten
(83%) of these had concordant results for the two tests
(growth within 48 h on screening media with or without
NaCl was the criterion for a positive result). Regarding the
possibility of selection, even if this method does select for
subclones that grow on screening media, its ability to do so
may represent detection of a strain-specific phenomenon
that could be of clinical importance if it occurs in vivo dur-
ing vancomycin therapy.
Having identified the positive screening phenotype
among our isolates, we sought to uncover clinical predic-
tors of bacteremia with isolates exhibiting this phenotype,
as well as to determine whether such bacteremia was asso-
ciated with adverse outcomes. Our results were negative
on both counts. The results were rendered more robust by
Emerging Infectious Diseases • Vol. 9, No. 6, June 2003 661
RESEARCH
Figure 2. a) Population analysis of parent isolates and reference
strains. PC3, vancomycin-intermediate Staphylococcus aureus
(VISA) reference strain (published vancomycin MIC 8 mg/L (19);
MIC 4 mg/L by our assay); ATCC, methicillin-resistant S. aureus
(MRSA) reference strain ATCC 33591 (MIC 1 mg/L by our assay);
clinical isolates exhibiting growth on screening media (MIC in
parentheses, in mg/L, followed by MIC of subclone)—302 (1, 4),
354 (0.5, 1), 1150 (1,2), 1203 (1,2); clinical isolates with no growth
on screening media (MIC in parentheses, in mg/L)—328 (1), 736
(1), 744 (1), 1149 (1). Isolates with growth on screening media are
represented by solid lines; isolates with no growth are represent-
ed by broken lines. Isolates 354 and 1150 were cultured from the
same patient, 14 months apart. b) Population analysis of an MRSA
bloodstream isolate exhibiting heterogeneously reduced suscepti-
bility to vancomycin, and its subclone, compared with reference
strains. ATCC, MRSA reference strain ATCC 33591 (MIC 1 mg/L
by our assay); PC3, VISA reference strain (published MIC 8 mg/L
(19); MIC 4 mg/Lby our assay); 1337, clinical isolate (MIC 1 mg/L);
1337d, subclone of 1337 grown on screening media (MIC 2 mg/L).
While the population curve representing 1337d closely resembles
that of PC3, this subclone did not meet MIC criteria for VISA. CFU,
colony-forming units.remaining essentially unchanged even as we varied the
definition of a positive screening result and performed an
institution-based subgroup analysis. More stringent defini-
tions of positivity other than those we explored (for exam-
ple, a requirement of growth on non–salt-containing
media), may have led us to undiscovered clinical differ-
ences between case-patients and controls.
These negative results can be interpreted in a number of
ways. First, our study may have lacked statistical power to
detect small differences between the groups in predictors
and outcomes. Given the degree to which most of the p
values deviate from statistical significance, however,
analysis of a substantially larger cohort would be required
to disprove such a claim. Moreover, our isolate cohort was
highly clonal, as a single type accounted for 69% of iso-
lates and the two most prominent types accounted for 84%.
This degree of clonality among pathogenic isolates of
MRSAmay bias any attempted comparison of clinical fea-
tures among the bacteremic patients (33).
Another possible explanation for our failure to detect
outcome differences between case-patients and controls is
the small degree of vancomycin exposure among all
patients in the cohort before blood was drawn for culture.
Only 17% (10 case-patients and 14 controls) of patients in
the case and control groups received vancomycin before
their blood was cultured, and the average amount of time
that vancomycin was used by case-patients and controls
before culture was approximately 1 day. Clinically, this
finding is understandable: Most patients in the cohort had
no reason to receive vancomycin before the growth of
MRSA. Still, as pharmacologic data were not uniformly
available before the patient’s hospitalization, we were able
to focus on receipt of vancomycin during the index admis-
sion only, thereby perhaps limiting our ability to distinguish
between study groups based on vancomycin exposure.
No difference may actually exist between bacteremia
with VSSA strains that exhibit heterogeneously reduced
susceptibility to vancomycin, as defined by growth on van-
comycin 4 mg/L screening agar, and homogeneously sus-
ceptible isolates. Such a conclusion would not rule out a
clinical difference associated with hetero-VISA bac-
teremia; because our cohort contained no such cases, we
cannot draw any conclusions regarding this question. Also,
we may have not detected a difference in outcomes
because we did not focus on the relevant ones. If, for
example, heterogeneously reduced vancomycin suscepti-
bility comes at the expense of a certain degree of virulence,
as suggested by Burnie et al. on the basis of a mouse model
(34), then we would not necessarily expect our case-
patients to have more hospital deaths or even a greater
length of stay in the hospital. We might, however, expect
to find several years from now that case-patients will have
a greater number of recurrent MRSA infections than will
controls, or longer durations of bacteremia during such
infections, due to failure of vancomycin to eradicate the
organism effectively.
Our results show that despite a subtle phenotypic differ-
ence in the MRSA isolates of a large minority of the
patients in our cohort, these patients were no different than
the reference group with respect to clinical characteristics,
antimicrobial use and other hospital exposures, and clini-
cal outcomes. These results add weight to assertions that
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Table 2. Descriptive characteristics of cohort 
Characteristic  Cases, n=61 (%)  Controls, n=88 (%)  p 
Mean age (y)  61±17  64±14  0.21 
Male  37 (61)  53 (60)  1.00 
Diabetes mellitus  30 (49)  34 (39)  0.24 
Renal disease  20 (33)  29 (33)  1.00 
Hemodialysis  10 (16)  12 (14)  0.65 
Cardiovascular disease  41 (67)  56 (64)  0.73 
Pulmonary disease  19 (31)  35 (40)  0.30 
Hepatic disease  8 (13)  7 (8)  0.41 
HIV  3 (5)  3 (3)  0.69 
Prosthetic joint or valve, or permanent pacemaker  13 (21)  11 (13)  0.18 
Hospitalization at same institution <30 days preceding culture  51 (84)  66 (75)  0.23 
Surgery during admission before culture  17 (28)  20 (23)  0.56 
Intensive care unit stay during admission before culture  33 (54)  38 (43)  0.24 
Severity of illness score
a      0.62 
aSeverity of illness is based on modified McCabe criteria (23): 1, severe underlying coexisting chronic condition, at imminent risk of death; 2, significant underlying 
coexisting chronic condition, not at imminent risk of death; 3, no significant underlying coexisting chronic condition. 
Table 3. Antibiotic exposures during hospitalization before culture 
Antibiotic exposure  Cases n=58 (%)  Controls n=84 (%)  p 
Administration of any antibiotic   27 (47)  45 (54)  0.50 
Administration of vancomycin  10 (17)  14 (17)  1.00 
Number of days of receiving vancomycin (mean)  1.2±4.8  1.0±3.5  0.88 clinical microbiology laboratories need not routinely
screen for vancomycin heteroresistance in S. aureus iso-
lates with vancomycin MICs in the susceptible range (2,8).
Additional studies with larger cohorts and a longer period
of follow-up are needed to validate these findings, deter-
mine whether they apply to infection with true hetero-
VISA, and evaluate outcomes suggestive of noneradicated,
indolent infection.
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